CTLA4 and hypophysitis: Immune checkpoint inhibitors (ICIs), particularly anti-CTLA-4 agents or combined CTLA-4/PD-1 regimens, are associated with an increased risk of hypophysitis, occurring in approximately 3–14% of treated patients.